- Home
- NRIX vs ZLAB Comparison
NRIX vs ZLAB Comparison
Compare NRIX & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRIX | ZLAB |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NRIX | ZLAB |
|---|---|---|
| Price | $14.80 | $17.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $30.58 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 891.7K | 695.3K |
| Earning Date | 04-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | N/A | ★ N/A |
| Revenue | $76,987,000.00 | ★ $460,156,000.00 |
| Revenue This Year | N/A | $14.46 |
| Revenue Next Year | $26.32 | $29.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 99.31 | 15.33 |
| 52 Week Low | $8.18 | $15.96 |
| 52 Week High | $22.50 | $44.34 |
Technical Indicators
Market Signals| Indicator | NRIX | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 45.37 |
| Support Level | $11.34 | $17.03 |
| Resistance Level | $16.47 | $19.49 |
| Average True Range (ATR) | 0.85 | 0.59 |
| MACD | 0.05 | -0.13 |
| Stochastic Oscillator | 36.53 | 28.72 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.